Takeda Pharmaceutical Statistics
Total Valuation
Takeda Pharmaceutical has a market cap or net worth of $42.50 billion. The enterprise value is $74.11 billion.
Important Dates
The last earnings date was Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | Mar 31, 2025 |
Share Statistics
Takeda Pharmaceutical has 1.59 billion shares outstanding. The number of shares has increased by 1.58% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.59B |
| Shares Change (YoY) | +1.58% |
| Shares Change (QoQ) | -0.21% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.57B |
Valuation Ratios
The trailing PE ratio is 58.97.
| PE Ratio | 58.97 |
| Forward PE | n/a |
| PS Ratio | 1.39 |
| Forward PS | 0.04 |
| PB Ratio | 0.92 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 7.37 |
| P/OCF Ratio | 6.02 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 9.17, with an EV/FCF ratio of 12.85.
| EV / Earnings | 102.83 |
| EV / Sales | 2.42 |
| EV / EBITDA | 9.17 |
| EV / EBIT | 24.71 |
| EV / FCF | 12.85 |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 0.73.
| Current Ratio | 1.01 |
| Quick Ratio | 0.44 |
| Debt / Equity | 0.73 |
| Debt / EBITDA | 4.19 |
| Debt / FCF | 5.87 |
| Interest Coverage | 4.15 |
Financial Efficiency
Return on equity (ROE) is 1.52% and return on invested capital (ROIC) is 2.27%.
| Return on Equity (ROE) | 1.52% |
| Return on Assets (ROA) | 1.91% |
| Return on Invested Capital (ROIC) | 2.27% |
| Return on Capital Employed (ROCE) | 3.82% |
| Revenue Per Employee | $620,829 |
| Profits Per Employee | $14,625 |
| Employee Count | 49,281 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 1.30 |
Taxes
In the past 12 months, Takeda Pharmaceutical has paid $447.02 million in taxes.
| Income Tax | 447.02M |
| Effective Tax Rate | 38.23% |
Stock Price Statistics
The stock price has increased by +7.09% in the last 52 weeks. The beta is 0.34, so Takeda Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | +7.09% |
| 50-Day Moving Average | 14.89 |
| 200-Day Moving Average | 14.15 |
| Relative Strength Index (RSI) | 37.93 |
| Average Volume (20 Days) | 2,162,193 |
Short Selling Information
| Short Interest | 4.68M |
| Short Previous Month | 5.03M |
| Short % of Shares Out | 0.30% |
| Short % of Float | 0.30% |
| Short Ratio (days to cover) | 1.88 |
Income Statement
In the last 12 months, Takeda Pharmaceutical had revenue of $30.60 billion and earned $720.73 million in profits. Earnings per share was $0.45.
| Revenue | 30.60B |
| Gross Profit | 20.04B |
| Operating Income | 3.00B |
| Pretax Income | 366.81M |
| Net Income | 720.73M |
| EBITDA | 8.08B |
| EBIT | 3.00B |
| Earnings Per Share (EPS) | $0.45 |
Full Income StatementBalance Sheet
The company has $2.57 billion in cash and $33.83 billion in debt, giving a net cash position of -$31.26 billion or -$19.72 per share.
| Cash & Cash Equivalents | 2.57B |
| Total Debt | 33.83B |
| Net Cash | -31.26B |
| Net Cash Per Share | -$19.72 |
| Equity (Book Value) | 46.32B |
| Book Value Per Share | 29.22 |
| Working Capital | 97.97M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $7.06 billion and capital expenditures -$1.34 billion, giving a free cash flow of $5.77 billion.
| Operating Cash Flow | 7.06B |
| Capital Expenditures | -1.34B |
| Free Cash Flow | 5.77B |
| FCF Per Share | $3.64 |
Full Cash Flow StatementMargins
Gross margin is 65.51%, with operating and profit margins of 9.80% and 2.36%.
| Gross Margin | 65.51% |
| Operating Margin | 9.80% |
| Pretax Margin | 3.82% |
| Profit Margin | 2.36% |
| EBITDA Margin | 26.42% |
| EBIT Margin | 9.80% |
| FCF Margin | 18.85% |